[Clinical and biochemical results during the treatment with marvelon, a new oral contraceptive (author's transl)].
Marvelon was tolerated without side effects by 338 women during 2,104 cycles. Although some errors of administration were made by patients there were no pregnancies. In contradistinction to other low dosage combination oral contraceptives this new oral contraceptive has a good control of the menstrual cycle. The incidence of clinical side effects was low. An over-suppression syndrome after the discontinuation of the treatment was not observed. Hormonal assays were done in order to investigate the difficult problems of oligomenorrhoea in adolescents with oral contraception. A marked inhibition of ovulation evident by low values of pituitary ovarian hormones was found. When the treatment was discontinued the majority of the patients showed ovulation in the first post-treatment cycle.
D000293:Adolescent; D000328:Adult; D015113:Androstane-3,17-diol / Q000097:blood; D002986:Clinical Trials as Topic; D003276:Contraceptives, Oral / Q000008:administration & dosage*; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage* / Q000494:pharmacology; D003687:Dehydroepiandrosterone / Q000097:blood; D017135:Desogestrel; D004958:Estradiol / Q000097:blood; D004970:Estrone / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D009652:Norpregnenes / Q000008:administration & dosage* / Q000494:pharmacology; D009839:Oligomenorrhea / Q000139:chemically induced; D010060:Ovulation / Q000187:drug effects; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood; D013739:Testosterone / Q000097:blood
D003276:Contraceptives, Oral; D003278:Contraceptives, Oral, Hormonal; D009652:Norpregnenes; D015113:Androstane-3,17-diol; D004970:Estrone; D013739:Testosterone; D003687:Dehydroepiandrosterone; D011374:Progesterone; D004958:Estradiol; D017135:Desogestrel; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone
Klinische und biochemische Resultate bei der Behandlung mit Marvelon--einem neuen steroidalen Ovulationshemmer.